Dynavax drops Tolamba on trial failure

Dynavax is dropping it's mid-stage ragweed allergy drug Tolamba as it failed to meet its primary efficacy endpoint. While the drug showed a measurable clinical benefit, reducing total nasal symptom score, the company said it wasn't worth pursuing development. Dynavax will now focus its efforts on Heplisav, its hepatitis B therapy.

"The current trial displayed an unexpectedly high degree of variability in the data set possibly due to the subjective nature of symptom scoring used to assess efficacy. A similar effect was observed in previous Tolamba clinical trials. We have concluded that this problem may be difficult to overcome in future clinical studies. We have therefore decided to discontinue clinical development of Tolamba," said Martin Sanders, MD, Executive Vice President and Chief Development Officer.

- see Dynavax's release for more

Suggested Articles

A month after scoring $1.6 billion from the U.S. government, Novavax is posting the first human data from its COVID-19 vaccine.

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.